IRD vs NVS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IRD and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IRD and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Opus Genetics develops treatments for eye disease, and it does so along two tracks that have very little to do with each other. The first is a portfolio of AAV gene therapies for inherited retinal diseases, which is where the ticker comes from: IRD is the industry abbreviation for inherited retinal disease. The lead program, OPGx-LCA5, is in a registrational Phase 3 trial for LCA5-associated blindness and carries FDA Rare Pediatric Disease, Orphan Drug and RMAT designations. Behind it sit OPGx-BEST1 for bestrophin-1 related retinal disease, plus earlier programs targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The second track is phentolamine ophthalmic solution 0.75%, which is already FDA-approved and sold by Viatris as RYZUMVI for reversing dilated pupils after an eye exam, and which is under FDA review for a much larger presbyopia indication with a target action date of October 17, 2026, which was still pending as of October 16. The company was formed when Ocuphire Pharma acquired the private Opus Genetics in late 2024 and took its name, which is why the SEC filer history runs back through Ocuphire and Rexahn.

Full IRD guide

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025. Revenue was about $56.7 billion in 2025, roughly 10% above 2024, and trailing twelve-month revenue is at about the same level with net income near $12.8 billion.

Full NVS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IRD drivers: The presbyopia decision due October 17, 2026; OPGx-LCA5 is in a registrational trial with a defined path.
• NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The trailing numbers do not support the valuation on any conventional measure, so essentially all of the market capitalization rests on events that have not happened yet. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IRD if you believe its drivers more; NVS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IRD and NVS guides.

IRD. No revenue multiple is informative here, because the roughly $9.9 million trailing figure is a development-cost reimbursement that shrinks as programs complete, not a commercial ramp. What the market is pricing instead is the presbyopia royalty stream if the sNDA clears on or around October 17, 2026, the LCA5 Phase 3 asset, and the BEST1 program, against roughly 83 million shares and a balance sheet that does not force a near-term raise. Analyst targets moved up after the September data (Chardan to $16, Wedbush to $13), and the mean target among 17 analysts tracked by Yahoo was about $13.41 in October 2026, far above the $3.87 share price, which says more about the spread of outcomes than about any likely path.

NVS. At about $151, NVS trades near 23 times trailing earnings but only about 15 times forward estimates, a gap that reflects reported profit depressed by the Entresto cliff and an expected rebound to about $9.80 of EPS in 2027. The analyst mean target of roughly $155 sits close to the current price, so the October 27 third-quarter report and how fast the growth brands keep absorbing the generic erosion matter more than any single trailing figure. Figures are approximate and tied to the asOf date; verify live numbers before acting.

Headline figures (approximate, October 2026): IRD shows market cap ~$320M at $3.87 (October 16, 2026), share price range 52-week high ~$7.07, low ~$1.70, revenue (ttm) ~$9.9M, almost entirely Viatris collaboration reimbursement, q2 2026 revenue ~$0.8M, down ~74% from a year earlier; NVS shows revenue (ttm) ~$56.7B; Q2 2026 revenue ~$14.95B, up ~1% year over year, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix offsetting Entresto's generic decline, margins (ttm) ~75% gross, ~35% operating, ~22.5% net, net income (ttm) ~$12.8B.

IRD and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IRD and NVS exposure against your real portfolio. It is not an investment adviser.